Evaluation of pediatric glioma outcomes using intraoperative MRI: a multicenter cohort study.


Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 04 02 2019
accepted: 19 03 2019
pubmed: 13 4 2019
medline: 18 12 2019
entrez: 13 4 2019
Statut: ppublish

Résumé

The use of intraoperative MRI (iMRI) during treatment of gliomas may increase extent of resection (EOR), decrease need for early reoperation, and increase progression-free and overall survival, but has not been fully validated, particularly in the pediatric population. To assess the accuracy of iMRI to identify residual tumor in pediatric patients with glioma and determine the effect of iMRI on decisions for resection, complication rates, and other outcomes. We retrospectively analyzed a multicenter database of pediatric patients (age ≤ 18 years) who underwent resection of pathologically confirmed gliomas. We identified 314 patients (mean age 9.7 ± 4.6 years) with mean follow-up of 48.3 ± 33.6 months (range 0.03-182.07 months) who underwent surgery with iMRI. There were 201 (64.0%) WHO grade I tumors, 57 (18.2%) grade II, 24 (7.6%) grade III, 9 (2.9%) grade IV, and 23 (7.3%) not classified. Among 280 patients who underwent resection using iMRI, 131 (46.8%) had some residual tumor and underwent additional resection after the first iMRI. Of the 33 tissue specimens sent for pathological analysis after iMRI, 29 (87.9%) showed positive tumor pathology. Gross total resection was identified in 156 patients (55.7%), but this was limited by 69 (24.6%) patients with unknown EOR. Analysis of the largest multicenter database of pediatric gliomas resected using iMRI demonstrated additional tumor resection in a substantial portion of cases. However, determining the impact of iMRI on EOR and outcomes remains challenging because iMRI use varies among providers nationally. Continued refinement of iMRI techniques for use in pediatric patients with glioma may improve outcomes.

Sections du résumé

BACKGROUND BACKGROUND
The use of intraoperative MRI (iMRI) during treatment of gliomas may increase extent of resection (EOR), decrease need for early reoperation, and increase progression-free and overall survival, but has not been fully validated, particularly in the pediatric population.
OBJECTIVE OBJECTIVE
To assess the accuracy of iMRI to identify residual tumor in pediatric patients with glioma and determine the effect of iMRI on decisions for resection, complication rates, and other outcomes.
METHODS METHODS
We retrospectively analyzed a multicenter database of pediatric patients (age ≤ 18 years) who underwent resection of pathologically confirmed gliomas.
RESULTS RESULTS
We identified 314 patients (mean age 9.7 ± 4.6 years) with mean follow-up of 48.3 ± 33.6 months (range 0.03-182.07 months) who underwent surgery with iMRI. There were 201 (64.0%) WHO grade I tumors, 57 (18.2%) grade II, 24 (7.6%) grade III, 9 (2.9%) grade IV, and 23 (7.3%) not classified. Among 280 patients who underwent resection using iMRI, 131 (46.8%) had some residual tumor and underwent additional resection after the first iMRI. Of the 33 tissue specimens sent for pathological analysis after iMRI, 29 (87.9%) showed positive tumor pathology. Gross total resection was identified in 156 patients (55.7%), but this was limited by 69 (24.6%) patients with unknown EOR.
CONCLUSIONS CONCLUSIONS
Analysis of the largest multicenter database of pediatric gliomas resected using iMRI demonstrated additional tumor resection in a substantial portion of cases. However, determining the impact of iMRI on EOR and outcomes remains challenging because iMRI use varies among providers nationally. Continued refinement of iMRI techniques for use in pediatric patients with glioma may improve outcomes.

Identifiants

pubmed: 30977059
doi: 10.1007/s11060-019-03154-7
pii: 10.1007/s11060-019-03154-7
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

271-280

Références

Pediatr Neurosurg. 2001 Jun;34(6):295-300
pubmed: 11455229
Pediatr Neurosurg. 2003 Feb;38(2):83-9
pubmed: 12566841
Acta Neurochir Suppl. 2003;85:137-42
pubmed: 12570149
Childs Nerv Syst. 2005 Feb;21(2):108-13; discussion 114
pubmed: 15565451
Childs Nerv Syst. 2006 Jul;22(7):674-8
pubmed: 16450131
Pediatr Neurosurg. 2006;42(2):74-80
pubmed: 16465075
Neurosurgery. 2006 Feb;58(1 Suppl):ONS44-51; discussion ONS44-51
pubmed: 16479628
J Neurosurg. 2010 Apr;112(4):736-43
pubmed: 19835472
J Neurosurg Pediatr. 2009 Nov;4(5):467-74
pubmed: 19877782
Acta Neurochir Suppl. 2011;109:97-102
pubmed: 20960327
Neurosurgery. 2011 Jul;69(1):194-205; discussion 205-6
pubmed: 21499143
Lancet Oncol. 2011 Oct;12(11):997-1003
pubmed: 21868284
Lancet Oncol. 2011 Oct;12(11):1062-70
pubmed: 21868286
J Neurosurg Pediatr. 2012 Mar;9(3):259-64
pubmed: 22380953
Turk Neurosurg. 2012;22(2):218-25
pubmed: 22437297
Childs Nerv Syst. 2012 Aug;28(8):1171-80
pubmed: 22684477
Surg Neurol Int. 2012;3(Suppl 2):S65-72
pubmed: 22826818
Childs Nerv Syst. 2013 Oct;29(10):1843-50
pubmed: 23673720
Eur J Surg Oncol. 2014 Mar;40(3):297-304
pubmed: 24411704
Pituitary. 2015 Feb;18(1):72-85
pubmed: 24599833
Neurosurgery. 2014 Aug;61 Suppl 1:145-54
pubmed: 25032543
AJNR Am J Neuroradiol. 2014 Dec;35(12):2382-7
pubmed: 25059696
PLoS One. 2015 Jun 26;10(6):e0131872
pubmed: 26115409
J Neurosurg Sci. 2017 Jun;61(3):233-244
pubmed: 26149222
Neurosurgery. 2016 Jun;78(6):775-86
pubmed: 26516822
Br J Neurosurg. 2016 Jun;30(3):313-7
pubmed: 26743016
Neurosurg Focus. 2016 Mar;40(3):E13
pubmed: 26926053
Turk Neurosurg. 2017;27(5):696-706
pubmed: 27651342
J Neurosurg Pediatr. 2017 Jan;19(1):77-84
pubmed: 27791707
Curr Med Res Opin. 2017 Apr;33(4):621-630
pubmed: 28008781
J Neurosurg. 2017 Oct;127(4):790-797
pubmed: 28059650
Neurosurg Rev. 2018 Jan;41(1):207-219
pubmed: 28265818
Curr Neurol Neurosci Rep. 2017 Feb;17(2):19
pubmed: 28271343
J Clin Oncol. 2017 Jul 20;35(21):2370-2377
pubmed: 28640698
J Neurosurg. 2018 May;128(5):1410-1418
pubmed: 28731401
Neurosurg Clin N Am. 2017 Oct;28(4):477-485
pubmed: 28917277
Neurosurg Rev. 2019 Jun;42(2):197-208
pubmed: 28921173
Clin Neurol Neurosurg. 2017 Dec;163:133-141
pubmed: 29101863
Cochrane Database Syst Rev. 2018 Jan 22;1:CD012788
pubmed: 29355914
Childs Nerv Syst. 2018 Apr;34(4):617-626
pubmed: 29460065

Auteurs

Michael Karsy (M)

Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA.

S Hassan Akbari (SH)

Department of Neurosurgery, Washington University School of Medicine, St. Louis, MO, USA.

David Limbrick (D)

Department of Neurosurgery, Washington University School of Medicine, St. Louis, MO, USA.

Eric C Leuthardt (EC)

Department of Neurosurgery, Washington University School of Medicine, St. Louis, MO, USA.

John Evans (J)

Department of Neurosurgery, Washington University School of Medicine, St. Louis, MO, USA.

Matthew D Smyth (MD)

Department of Neurosurgery, Washington University School of Medicine, St. Louis, MO, USA.

Jennifer Strahle (J)

Department of Neurosurgery, Washington University School of Medicine, St. Louis, MO, USA.

Jeffrey Leonard (J)

Department of Neurosurgery, Nationwide Children's Hospital, Columbus, OH, USA.

Samuel Cheshier (S)

Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA.

Douglas L Brockmeyer (DL)

Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA.

Robert J Bollo (RJ)

Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA.

John R Kestle (JR)

Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA.

John Honeycutt (J)

Department of Neurosurgery, Cook Children's Neurosciences, Forth Worth, TX, USA.

David J Donahue (DJ)

Department of Neurosurgery, Cook Children's Neurosciences, Forth Worth, TX, USA.

Richard A Roberts (RA)

Department of Neurosurgery, Cook Children's Neurosciences, Forth Worth, TX, USA.

Daniel R Hansen (DR)

Department of Neurosurgery, Cook Children's Neurosciences, Forth Worth, TX, USA.

Jay Riva-Cambrin (J)

Department of Neurosurgery, University of Calgary, Calgary, AB, Canada.

Garnette Sutherland (G)

Department of Neurosurgery, University of Calgary, Calgary, AB, Canada.

Clair Gallagher (C)

Department of Neurosurgery, University of Calgary, Calgary, AB, Canada.

Walter Hader (W)

Department of Neurosurgery, University of Calgary, Calgary, AB, Canada.

Yves Starreveld (Y)

Department of Neurosurgery, University of Calgary, Calgary, AB, Canada.

Mark Hamilton (M)

Department of Neurosurgery, University of Calgary, Calgary, AB, Canada.

Ann-Christine Duhaime (AC)

Department of Neurosurgery, Massachusetts General Hospital for Children, Boston, MA, USA.

Randy L Jensen (RL)

Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA. neuropub@hsc.utah.edu.
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. neuropub@hsc.utah.edu.

Michael R Chicoine (MR)

Department of Neurosurgery, Washington University School of Medicine, St. Louis, MO, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH